vers la météo de la validation par utilisateur

Ingenuity407

precedent - 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 - suivant

Phrase 17 - PMID ?

NS 220 , an agonist of __SP__ __NODE__ protein , is in Phase I clinical trial to treat hyperlipidemia .


Non annotée
Je ne sais pas
Je n'ai pas trouvé d'analyse satisfaisante


Commentaires :
Analyse 0 
                                                   +----------------COMP:V-N(in)---------------+        
     +-------------------SUBJ:V-N------------------+      +-------------MOD_ATT:N-N------------+        
     |          +-------COMP:N-N(of)-------+       |      |         +-------MOD_ATT:N-ADJ------+        
     |          |          +-MOD_ATT:N-ADJ-+       |      |         |      +----MOD_ATT:N-N----+        
     +---APPOS--+          |       +MOD_ATT+       |      |         |      |        +MOD_ATT:N-+        
     |          |          |       |       |       |      |         |      |        |          |        
 NS 220 , an agonist of __SP__ __NODE__ protein , is in Phase I clinical trial to treat hyperlipidemia .
APPOS (@card@,agonist)
COMP:N-N(of) (agonist,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
SUBJ:V-N (be,@card@)
COMP:V-N(in) (be,hyperlipidemia)
MOD_ATT:N-N (hyperlipidemia,phase)
MOD_ATT:N-ADJ (hyperlipidemia,clinical)
MOD_ATT:N-N (hyperlipidemia,trial)
MOD_ATT:N-N (hyperlipidemia,treat)
Analyse 1 
                                                   +----------------COMP:V-N(in)---------------+        
     +-------------------SUBJ:V-N------------------+      +-------------MOD_ATT:N-N------------+        
     |          +-------COMP:N-N(of)-------+       |      |         +-------MOD_ATT:N-ADJ------+        
     |          |          +-MOD_ATT:N-ADJ-+       |      |         |      +----MOD_ATT:N-N----+        
     +---APPOS--+          |       +MOD_ATT+       |      |         |      |        +MOD_ATT:N-+        
     |          |          |       |       |       |      |         |      |        |          |        
 NS 220 , an agonist of __SP__ __NODE__ protein , is in Phase I clinical trial to treat hyperlipidemia .
APPOS (@card@,agonist)
COMP:N-N(of) (agonist,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
SUBJ:V-N (be,@card@)
COMP:V-N(in) (be,hyperlipidemia)
MOD_ATT:N-N (hyperlipidemia,phase)
MOD_ATT:N-ADJ (hyperlipidemia,clinical)
MOD_ATT:N-N (hyperlipidemia,trial)
MOD_ATT:N-N (hyperlipidemia,treat)